Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Pharmagreen Biotech Inc. (OTC Markets: PHBI) is developing its line of nutraceutical products, a proprietary blend of therapeutic plants and mushrooms. Pharmagreen's first new product, MaxGenomic(TM) Supplement, is a proprietary blend, formulated in the U. S. A., of nine medicinal mushrooms and six ... Pharmagreen Biotech Inc. (OTC Markets: PHBI) is developing its line of nutraceutical products, a proprietary blend of therapeutic plants and mushrooms. Pharmagreen's first new product, MaxGenomic(TM) Supplement, is a proprietary blend, formulated in the U. S. A., of nine medicinal mushrooms and six medicinal plants to help support the human mind and body. This supplement is produced in a U.S.A cGMP facility, in enteric capsules to enhance the bioavailability of the MaxGenomic(TM) supplement. Pharmagreen is also completing its research for its elixir, sublingual version, to provide immediate help and support to those who push their mental and physical capacity to their limits. Utilizing the Company's expertise in plant genetics, tissue culture, Pharmagreen's transgenic program uses the current technologies to research and create nutraceutical formulations as daily supplements, with the potential to improve lives and address a wide variety of aliments. Mehr anzeigen
PHBI – Pharmagreen Announces Affirmed MOU To Acquire Licensed California Cannabis Company CARSON CITY, NV, Thursday, January 06, 2022 -- InvestorsHub NewsWire...
CARSON CITY, NV -- December 16, 2021 -- InvestorsHub NewsWire -- Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), today continued in the release of a series of management updates from CEO Peter...
CARSON CITY, NV -- Decembger 10, 2021 -- InvestorsHub NewsWire -- Pharmagreen Biotech, Inc., (OTC PINK: PHBI), today released a second management update form CEO Peter Wojcik. Today’s update...
Carson City, NV -- December 2, 2021 -- InvestorsHub NewsWire -- Pharmagreen Biotech, Inc., (OTC Pink: PHBI), today released a management update from CEO Peter Wojcik. The update is the first...
December 1, 2021 -- InvestorsHub NewsWire -- via pennymillions -- Tissue culture itself is not new, but its new to the cannabis industry. See a recent MJBizDaily...
November 11, 2021 -- InvestorsHub NewsWire -- via pennymillions -- Pharmagreen Biotech, Inc. (PHBI) continues to hover at its $0.027 200 Day Moving Average (MA) on the verge of a...
CARSON CITY, NV -- November 11, 2021 -- InvestorsHub NewsWire -- Pharmagreen Biotech, Inc., (OTC PINKS: PHBI), is pleased to announce that in advance of its entry into the multi-billion...
November 9, 2021 -- InvestorsHub NewsWire -- via pennymillions -- Pharmagreen Biotech, Inc. (PHBI) trading volume has more than double since the original Breakout Alert earlier...
November 9, 2021 -- InvestorsHub NewsWire -- via pennymillions -- Pharmagreen Biotech, Inc. (PHBI) is on the verge of becoming the next big name in the cannabis sector. The company has...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.00055 | 32.3529411765 | 0.0017 | 0.0027 | 0.0017 | 11278101 | 0.00231274 | CS |
| 4 | 0.00105 | 87.5 | 0.0012 | 0.0027 | 0.0012 | 4366999 | 0.002173 | CS |
| 12 | 5.0E-5 | 2.27272727273 | 0.0022 | 0.003 | 0.0012 | 2556431 | 0.00206928 | CS |
| 26 | 0.00135 | 150 | 0.0009 | 0.0047 | 0.0007 | 4585905 | 0.00254458 | CS |
| 52 | 0.00155 | 221.428571429 | 0.0007 | 0.0047 | 0.0006 | 3075261 | 0.00212661 | CS |
| 156 | -0.01425 | -86.3636363636 | 0.0165 | 0.0199 | 0.000195 | 2965707 | 0.00171544 | CS |
| 260 | -0.41775 | -99.4642857143 | 0.42 | 0.825 | 0.000195 | 3123066 | 0.01441996 | CS |
| Symbol | Preis | Vol. |
|---|---|---|
| SPRVSupurva Healthcare Group Inc (PK) | US$ 0,0001 (-50,00%) | 743,04M |
| GRLFGreen Leaf Innovations Inc (PK) | US$ 0,0001 (9.900,00%) | 403,59M |
| PDGOParadigm Oil and Gas Inc (PK) | US$ 0,0001 (-50,00%) | 224,27M |
| GTCHGBT Technologies Inc (PK) | US$ 0,0001 (0,00%) | 173,13M |
| QEDNQED Connect Inc (PK) | US$ 0,0002 (0,00%) | 154,6M |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
